GVHD and Second Primary Hematologic Malignancy Risk
Yes, graft-versus-host disease (GVHD), particularly moderate-to-severe chronic GVHD, increases the risk of developing second primary hematologic malignancies after allogeneic hematopoietic stem cell transplantation.
Evidence for Increased Risk
The most recent and highest quality evidence demonstrates that moderate-to-severe chronic GVHD is independently associated with a 54% increased risk of developing second primary malignancies (HR 1.54, p=0.02) 1. This 2025 study of 1418 patients with over 6,000 person-years of follow-up found that HSCT recipients were 2.45 times more likely to develop a malignancy compared to the general population 1.
A 2024 study specifically examining severe aplastic anemia patients post-transplant confirmed that moderate-to-severe chronic GVHD was a significant independent risk factor for subsequent malignancy, with patients showing a 3.54-fold higher cancer incidence than the age- and sex-matched general population 2.
Mechanism and Pathophysiology
The biological mechanism underlying this increased risk involves chronic immune dysregulation and persistent inflammation. A 2010 murine study demonstrated that GVHD itself—even without radiation—induces genomic damage in hematopoietic cells, with significantly increased micronuclei frequencies and elevated TNF-alpha levels, indicating inflammatory-mediated DNA damage 3.
Clinical Implications by GVHD Severity
Chronic GVHD Characteristics Associated with Higher Risk:
- Extensive grade chronic GVHD: HR 1.60 for non-malignant late effects 4
- Severe chronic GVHD: HR 2.25 for complications 4
- Both mucocutaneous and visceral organ involvement: HR 1.59 4
- Interrupted onset type: HR 1.57 4
Important Distinction:
While chronic GVHD increases overall malignancy risk, a 2022 pediatric study found that chronic GVHD was more closely associated with non-malignant late effects than with subsequent neoplasms specifically (HR 1.37 for non-malignant effects vs HR 1.30 for subsequent neoplasms, with the latter not reaching statistical significance) 4. However, this does not negate the overall increased cancer risk in adults with chronic GVHD.
Protective Factors
Notably, certain GVHD prophylaxis strategies may reduce second malignancy risk. The combination of anti-thymocyte globulin with post-transplant cyclophosphamide (ATG-PTCy) was independently associated with a 35% reduction in second primary malignancy risk (HR 0.65, p=0.02) 1.
Surveillance Recommendations
Given this established risk, active surveillance and screening for second primary malignancies in transplant survivors with chronic GVHD is paramount 1, 2. The 2020 NCCN guidelines specifically note that late complications after day 100 include secondary malignancies 5, and the 2024 Diamond-Blackfan Anemia guidelines emphasize that "DBA syndrome-specific cancer risk may be increased following HSCT" and recommend close monitoring beyond standard post-transplant follow-up 6.
Critical Caveats
- Duration of immunosuppressive therapy for GVHD treatment was NOT significantly associated with subsequent neoplasms in the pediatric cohort 4, suggesting the GVHD itself rather than its treatment drives malignancy risk
- Hematologic second malignancies carry worse prognosis: 3-year survival from diagnosis was significantly inferior for hematologic versus solid tumor second malignancies (HR 2.40) 1
- Other risk factors compound the effect: older patient age (HR 1.10 per year) and use of total body irradiation independently increase risk 1, 2, 4
Bottom line: Patients with moderate-to-severe chronic GVHD require intensified, lifelong surveillance for second primary malignancies, with particular attention to hematologic malignancies given their poor prognosis when they occur.